Ani Pharmaceuticals (ANIP) EBIT Margin (2011 - 2026)

Ani Pharmaceuticals has disclosed EBIT Margin across 16 years of filings, most recently posting 16.38% for Q1 2026.

• EBIT Margin for Q1 2026 came in at 16.38%, up 309.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 13.4% (up 1244.0% YoY), and the FY2025 annual result was 12.58%, up 1248.0% from the prior year.
• EBIT Margin came in at 16.38% for Q1 2026 at Ani Pharmaceuticals, up from 14.07% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 16.38% in Q1 2026 to a low of 29.77% in Q1 2022.
• The 5-year median for EBIT Margin is 6.57% (2025), against an average of 3.29%.
• Peak annual rise in EBIT Margin reached 4087 bps in 2022, while the deepest fall reached 5696 bps in 2022.
• Ani Pharmaceuticals' EBIT Margin stood at 1.93% in 2022, then surged by 165 bps to 5.11% in 2023, then sank by 145 bps to 2.3% in 2024, then soared by 713 bps to 14.07% in 2025, then grew by 16 bps to 16.38% in 2026.
• The last three EBIT Margin figures came in at 16.38% (Q1 2026), 14.07% (Q4 2025), and 15.91% (Q3 2025), per Business Quant data.